An interventional study of Nerivio treatment in Temporomandibular Disorder and Orofacial Pain, sponsored by Theranica. Recruiting at 4 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Theranica · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Temporomandibular Joint Disorders with a site in United States — 17 open to participants now, 20 under way, none of them phase 3. Temporomandibular Joint Disorders · United States.
Among the 59 studies in Temporomandibular Joint Disorders with a site in United States, this one is the 16th largest by planned enrollment of the 46 interventional ones that give a count, is one of 6 that started in 2026, is one of 29 with no phase, reaches primary completion later than 10 of the 19 other live ones, and was the 56th registered.
591 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.
Browse Temporomandibular Joint Disorders studies →17 of the 59 studies in Temporomandibular Joint Disorders with a site in United States are open now. Recruiting first, the newest first:
Arpana Church · Sites in United States
Ages 18–50 · Women only
University of Minnesota · Sites in United States
Ages 18+
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 18–65
Boston University · Sites in United States
Ages 30–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Temporomandibular Joint Disorders studies recruiting now, 26 (35%) set no upper age limit and 45 (60%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 2 · Phase 4 1
First in 1997; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 45 across 415 interventional studies indexed under Temporomandibular Joint Disorders.
Median enrollment 60 across the 46 interventional studies, 180 across the 11 observational. Of the 36 that completed or were terminated, 16 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 59 have an industry lead sponsor. The 10 most frequent:
Theranica is the lead sponsor of 27 studies on the registry; 3 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Theranica has 1 study filed under Temporomandibular Joint Disorders — fewer than ten, so there is no comparison to draw.
10 of the studies in Temporomandibular Joint Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06977100University of FloridaJournaling Intervention for Temporomandibular Disorder (TMD) and Chronic Overlapping Pain | 2026-11 |
| NCT07226505Loyola UniversityEffects of Core Strengthening Exercises for Treating TMD | 2026-12-01 |
| NCT06617494University of MinnesotaEndogenous Pain Inhibition Deficiency in Chronic TMD Pain | 2026-12-31 |
| NCT07153107University of MinnesotaR01_Pilot Jaw Muscle Phenotypes | 2027-01-12 |
| NCT04376333UConn HealthIndividualized Assessment and Treatment for TMD | 2027-03-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 59 studies in Temporomandibular Joint Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Temporomandibular disorders (TMD) encompass a group of conditions involving the masticatory muscles, temporomandibular joint (TMJ), and associated structures. TMD is the most common cause of non-odontogenic orofacial pain and is the second most commonly occurring musculoskeletal condition. Up to 70% of the general population experiences signs and/or symptoms of TMD, with headache presenting as one of the most common manifestations. Recent studies highlight the comorbid presence of headache and TMD, hypothesizing that a relationship likely exists between the two conditions. Headache severity has also been associated with the number of TMD symptoms such that the prevalence of headache in TMD patients. A key mechanism underlying both TMD and migraine is the deficiency in Conditioned Pain Modulation (CPM), a descending inhibitory pathway that regulates pain processing. CPM impairment has been implicated in chronic pain states, including both migraine and TMD, contributing to their frequent co-occurrence and shared pathophysiology.
Remote Electrical Neuromodulation (REN) is an emerging non-pharmacological intervention that exerts its analgesic effects by activating the CPM system, which is deficient in individuals with TMD and migraine. The Nerivio REN wearable device is FDA-cleared for acute and/or migraine prevention, in patients 8 years of age or older. Given the evidence linking CPM dysfunction to TMD pathogenesis, REN presents a promising therapeutic approach to addressing both the underlying pain dysregulation and symptom burden in affected patients.
Temporomandibular disorders (TMD) encompass a group of conditions involving the masticatory muscles, temporomandibular joint (TMJ), and associated structures. TMD is the most common cause of non-odontogenic orofacial pain and is the second most commonly occurring musculoskeletal condition. Up to 70% of the general population experiences signs and/or symptoms of TMD, with headache presenting as one of the most common manifestations. Recent studies highlight the comorbid presence of headache and TMD, hypothesizing that a relationship likely exists between the two conditions. Accordingly, a recent systematic review and meta-analysis supported a positive association between pain-related TMD, migraine, and chronic tension-type headaches. Other studies demonstrated that, among patients seeking care for headaches, the prevalence of those presenting with TMD symptoms ranged from 52-55%. Headache severity has also been associated with the number of TMD symptoms such that the prevalence of headache in TMD patients with one TMD symptom was 57%, with two symptoms was 65%, and with three or more symptoms was 73%. Notably, the Orofacial Pain: Prospective Evaluation and Risk Assessment (OPPERA) study -the largest population-based study in adults designed to identify risk factors associated with the onset and persistence of TMD - showed that prior headaches were a significant risk factor for the development of first-onset TMD symptoms9. After the development of TMD, both headache severity and frequency were shown to increase in the TMD group compared to healthy participants. Specifically, the prevalence of migraine episodes increased 10-fold in the group that developed TMD symptoms. Finally, clinical studies revealed that, when TMD is successfully treated, headache symptoms also tend to resolve, suggesting a role of TMD in the pathophysiological process.
A key mechanism underlying both TMD and migraine is the deficiency in Conditioned Pain Modulation (CPM), a descending inhibitory pathway that regulates pain processing. CPM impairment has been implicated in chronic pain states, including both migraine and TMD, contributing to their frequent co-occurrence and shared pathophysiology. Remote Electrical Neuromodulation (REN) is an emerging non-pharmacological intervention that exerts its analgesic effects by activating the CPM system, which is deficient in individuals with TMD and migraine. The Nerivio REN wearable device is FDA-cleared for acute and/or migraine prevention, in patients 8 years of age or older. It is a prescription use, self-administered device for use in the home environment at the onset of migraine headache or aura for acute treatment, or every other day for preventive treatment. By enhancing endogenous pain inhibition, REN has been shown to provide effective relief in migraine, and its application in TMD is expected to yield similar clinical benefits. Given the evidence linking CPM dysfunction to TMD pathogenesis, REN presents a promising therapeutic approach to addressing both the underlying pain dysregulation and symptom burden in affected patients.
The aim of this study is to evaluate the safety and efficacy of Nerivio Infinity for the management of headache, orofacial pain and TMD related symptoms.
This is an open-label, single arm study to determine whether REN can be utilized for the management of TMD-related pain and other symptoms. 40 participants (ages 12 years and older) with a TMD diagnosis will be enrolled. Treatment will be performed once daily for 45 minutes per treatment, for 6 weeks. Daily treatment ensures consistent neuromodulation, is expected to reduce overall pain severity, and to maintain CPM activation. TMD pathophysiology supports daily use: TMD involves central sensitization and chronic engagement of the trigeminal system, similar to migraine. Unlike migraine, where individual attacks may be separated by pain-free periods, TMD pain is often persistent or recurrent on a near-daily basis. Moreover, daily use ensures sustained neuromodulatory effects to prevent worsening of pain flares while improving functional jaw mobility. Daily use is expected to reduce overall pain severity, attack frequency, and functional impairment (aligning with migraine prevention goals). Additional acute use (as-needed adjunct to daily treatment) will be permitted and is expected to address pain flare-ups that may still occur despite daily neuromodulation.
The study will consist of two main phases:
4-week baseline phase- in which participants will report their symptoms daily via an electronic app diary (with no intervention); 6-week intervention phase- in which eligible participants perform once daily treatments using Nerivio Infinity device, and continue to report symptoms daily via the app.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has any of the following medical conditions:
1.1 Uncontrolled seizures/epilepsy 1.2 Benign and malignant TMJ and masticatory muscle tumors 1.3 Presence of implanted electrical device
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nerivio, a Remote electrical neuromodulation (REN) device. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application. Treatment regime - once a day
Device: Nerivio treatment
Nerivio, a Remote electrical neuromodulation (REN) device. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
Change in daily maximum-pain level
The change in daily maximum orofacial pain level, by comparing the average daily maximum-pain level in the 4 weeks of the baseline phase (weeks 1-4) to the last 4 weeks of the intervention phase (weeks 7-10), measured by Numeric Rating Scale score (NRS, 0-10). Pain level will be taken from any of the orofacial locations specified in the daily diary (jaw, head, neck, ear, eye, face, teeth), as reported in a daily diary, through a study specific smartphone application. Numeric Rating Scale score is on a scale of 0 (no pain) to 10 (worst pain),
Time frame: 10 weeks
Change in self-reported Jaw Functional Limitation Scale (JFLS)
Change in the self-reported Jaw Functional Limitation Scale (JFLS, 0-10) from the end of the baseline phase (visit 2) to following the intervention phase at week 10 (visit 3) to compare post-treatment changes in limitations of jaw function. Jaw Functional Limitation Scale score is from 0 (no limitation) to 10 (severe limitation).
Time frame: 10 weeks
Change in number of days with orofacial pain
Change in number of days with any orofacial pain, comparing the 4 weeks of the baseline phase (weeks 1-4) to the last 4 weeks of the intervention phase (weeks 7-10).
Time frame: 10 weeks
Change in Patient Global Impression of Change (PGIC) scores
Compare average Patient Global Impression of Change (PGIC) scores regarding orofacial pain following the intervention at visit 3, to assess if patients perceive greater improvement with using REN. Patient Global Impression of Change score is from 1 (very much improved) to 7 (Very much worse).
Time frame: 10 weeks
Responder rate of at least 30% reduction in daily maximum-pain level
Proportion of patients showing \>30% reduction in average daily maximum-pain level, by comparing the 4 weeks of the baseline phase (weeks 1-4) to the last 4 weeks of the intervention phase (weeks 7-10), measured by Numeric Rating Scale score (NRS, 0-10). Numeric Rating Scale score is on a scale of 0 (no pain) to 10 (worst pain),
Time frame: 10 weeks
Change in Maximum Mouth Opening (MMO)
Change in Maximum Mouth Opening (MMO) will be measured at the end of the baseline at visit 2 and at the end of intervention at visit 3, recorded by the health care provider, and measured in mm.
Time frame: 10 weeks
Change in Jaw pain level
: Change in Jaw pain level by comparing the average daily maximum-pain level in the 4 weeks of the baseline phase (weeks 1-4) to the last 4 weeks of the intervention phase (weeks 7-10), measured by Numeric Rating Scale score (NRS, 0-10). Numeric Rating Scale score is on a scale of 0 (no pain) to 10 (worst pain),
Time frame: 10 weeks
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.
Of 246 interventional studies with no phase under Temporomandibular Joint Disorders, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's planned 12 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Jan 2027 → Jun 2027 and completion Jan 2027 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Temporomandibular Joint Disorders →